Clinical Trials Browser

Breast Neoplasms, Stomach Neoplasms, Triple Negative Breast Neoplasms

Breast Neoplasms

Colorectal Neoplasms

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

Breast Neoplasms, Colorectal Neoplasms

HER2-positive Breast Cancer

Lymphoma, Non-Hodgkin, Multiple Myeloma

Adenocarcinoma, Rectal Neoplasms

Colorectal Neoplasms

Adenocarcinoma Of Esophagus, Esophageal Neoplasms, Gallbladder Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

Breast Neoplasms, Meningeal Neoplasms

Breast Neoplasms, Neoplasm Metastasis, Neoplasms

Lymphoma, Non-Hodgkin, Multiple Myeloma, Neoplasms

Breast Neoplasms

Colonic Neoplasms

Breast Neoplasms

Brain Neoplasms

HER2-positive Breast Cancer

Breast Neoplasms

Brain Neoplasms, Breast Neoplasms

Metastatic Breast Cancer With a Isolated Brain Progression

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms, Meningeal Neoplasms

Breast Neoplasms

Anatomic Stage II Breast Cancer AJCC v8

Breast Neoplasms, Neoplasm Metastasis, Triple Negative Breast Neoplasms

HER2-positive Breast Cancer

Clinical Trials

A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors

HER2CLIMB-05

MOUNTAINEER-03

I-SPY

Safety and Pharmacokinetics of Tucatinib (MK-7119) in Chinese Participants With Cancer (MK-7119-002)

BREnnA

CAPTUR

A Study of Tucatinib and Trastuzumab in People With Rectal Cancer

ASCEND-CRC: Profiling and Targeting Dynamic Tumor Resistance in Patients With Metastatic Colorectal Cancer

Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers

Tucatinib, Trastuzumab and Capecitabine With Brain and/or Spinal Radiotherapy (XRT) in Patients With HER2+, HER2 Mutated and/or HER2-amplified Metastatic Breast Cancer and Leptomeningeal Disease: A Multi-centre Phase II, Single Arm Feasibility Study

H3RAKLES

TAPUR

MK-1022-009

ERASE-CRC

MK-7119-001

Tucatinib, Trastuzumab, and Capecitabine With SRS for Brain Metastases From HER-2 Positive Breast Cancer

A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer

TrasTUCAN

DB-07

InTTercePT

HER2CLIMB-04

PIKture-01

Tucatinib, Trastuzumab, and Capecitabine for the Treatment of HER2+ LMD

The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer

Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer

PRE-I-SPY-PI

TUC-TOC